TPEX:6744

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

NT$428.1m

Last Updated

2021/06/11 08:35 UTC

Data Sources

Company Financials

Executive Summary

Feng Chi Biotech Corp. provides preimplantation genetic testing, prenatal testing, life science, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services. More Details


Snowflake Analysis

Flawless balance sheet with solid track record.

Share Price & News

How has Feng Chi Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6744 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 6744's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

0%

6744

0.9%

TW Healthcare

0.2%

TW Market


1 Year Return

-17.4%

6744

18.8%

TW Healthcare

48.5%

TW Market

Return vs Industry: 6744 underperformed the TW Healthcare industry which returned 15.2% over the past year.

Return vs Market: 6744 underperformed the TW Market which returned 44.3% over the past year.


Shareholder returns

6744IndustryMarket
7 Day0%0.9%0.2%
30 Day-2.5%6.1%7.8%
90 Day-0.7%7.5%5.6%
1 Year-15.3%-17.4%22.6%18.8%53.6%48.5%
3 Yearn/a47.0%32.7%70.9%51.3%
5 Yearn/a79.4%49.3%139.1%96.6%

Long-Term Price Volatility Vs. Market

How volatile is Feng Chi Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Feng Chi Biotech undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 6744 (NT$27.8) is trading below our estimate of fair value (NT$56.55)

Significantly Below Fair Value: 6744 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 6744 is good value based on its PE Ratio (16.9x) compared to the TW Healthcare industry average (17.3x).

PE vs Market: 6744 is good value based on its PE Ratio (16.9x) compared to the TW market (17.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6744's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6744's PB Ratio (1.9x) is in line with the TW Healthcare industry average.


Future Growth

How is Feng Chi Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.7%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Feng Chi Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Feng Chi Biotech performed over the past 5 years?

14.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6744 has high quality earnings.

Growing Profit Margin: 6744's current net profit margins (14.2%) are higher than last year (10%).


Past Earnings Growth Analysis

Earnings Trend: 6744's earnings have grown by 14.7% per year over the past 5 years.

Accelerating Growth: 6744's earnings growth over the past year (46%) exceeds its 5-year average (14.7% per year).

Earnings vs Industry: 6744 earnings growth over the past year (46%) exceeded the Healthcare industry -2.6%.


Return on Equity

High ROE: 6744's Return on Equity (11.3%) is considered low.


Financial Health

How is Feng Chi Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: 6744's short term assets (NT$261.6M) exceed its short term liabilities (NT$56.4M).

Long Term Liabilities: 6744's short term assets (NT$261.6M) exceed its long term liabilities (NT$2.6M).


Debt to Equity History and Analysis

Debt Level: 6744 is debt free.

Reducing Debt: 6744 has not had any debt for past 5 years.

Debt Coverage: 6744 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 6744 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Feng Chi Biotech current dividend yield, its reliability and sustainability?

4.14%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 6744's dividend (4.14%) is higher than the bottom 25% of dividend payers in the TW market (2.06%).

High Dividend: 6744's dividend (4.14%) is low compared to the top 25% of dividend payers in the TW market (5.01%).


Stability and Growth of Payments

Stable Dividend: Too early to tell whether 6744's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if 6744's dividend payments are increasing as they only just started paying a dividend.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (69.7%), 6744's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Feng Chi Biotech has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Feng Chi Biotech Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Feng Chi Biotech Corp.
  • Ticker: 6744
  • Exchange: TPEX
  • Founded: NaN
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: NT$428.120m
  • Shares outstanding: 15.40m
  • Website: https://www.fcbiotech.com.tw

Number of Employees


Location

  • Feng Chi Biotech Corp.
  • 1, No.5, Shaoxing North Street
  • 5th Floor
  • Taipei
  • 100
  • Taiwan

Listings


Biography

Feng Chi Biotech Corp. provides preimplantation genetic testing, prenatal testing, life science, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services....


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/11 08:35
End of Day Share Price2021/06/08 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.